Physician profile
Donald E Loveless
NPI 1124027693
$474.87
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $53.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118.92 | 2019 | |
| Therapeuticsmd, INC. | $54.58 | 2019-2020 | |
| Pfizer INC. | $49.30 | 2019 | |
| Roche Diagnostics Corporation | $46.86 | 2019 | |
| Amag Pharmaceuticals, INC. | $42.88 | 2019-2020 | |
| Minerva Surgical, INC | $27.30 | 2019 | |
| Daiichi Sankyo INC. | $18.91 | 2019 | |
| Coloplast Corp | $17.06 | 2019 | |
| Astellas Pharma US INC | $16.83 | 2019 | |
| Davol INC. | $15.75 | 2019 | |
| Exeltis, USA INC. | $15.12 | 2019 | |
| Avion Pharmaceuticals | $14.80 | 2019 | |
| Acessa Health INC. | $12.81 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.42 | 2019 | |
| Allergan, INC. | $11.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Loveless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.